The measurement of plasma alkaline phosphatase (ALP; EC 3.1.3.1) activity is clinically useful in screening for metabolic bone disease in pre term infants.t-' A raised plasma ALP activity is not, in itself, diagnostic of metabolic bone disease, nor does it identify the aetiology; it may, in some cases, be within the reference range even in the presence of radiological evidence of disease.' However, if the plasma ALP activity exceeds six times the upper adult reference limit, it is recommended that radiological examination of long timing, with respect to postnatal age of the peak plasma ALP activity, appears to differ depending on the gestational age of the infant. In order to evaluate the effect of two age variables on plasma ALP activity, gestational age and postnatal age, a three-dimensional computer assisted plot was constructed.
All infants admitted to a single Special Care Baby Unit over a one-year period and who were born before 36 weeks gestational age and weighed less than 1500 g at birth, were entered into the bones is required in order to exclude active disease. ' A rise, peak and fall in plasma ALP activity is a normal phenomenon in preterm infants! but the study. The gestational age at birth was assessed from first trimester ultrasound ageing together with a clinical Dubowitz assessment at birth. Any infant who developed clinical or radiological evidence of metabolic bone disease was excluded from the study. Plasma ALP activity was assayed by a previously reported method.' One hundred and fifty-eight measurements of plasma ALP activity were included from 107 infants; there was a median of 3 data points per postnatal age period for different gestational ages.
In those infants born between 27 and 29 weeks of gestation, there was a peak of plasma ALP activity at approximately 4-5 weeks postnatal age (Fig. I) . However, the overall timing of the peak activity varied with the gestational age at birth. There was a significant difference (P < 0,05, Mann-Whitney U test) between the peak and the trough plasma ALP activities observed between 4 and 7 weeks postnatal age overall, which was dependent on the gestational age of the infants. Peak plasma ALP activities occurred at 29 weeks gestational age (median activity 1406 U/L, range 845-1980) and at 32 weeks gestational age (median 982 U/L, range 800-1229), and troughs occurred at 31 weeks gestational age (median 858 U/L, range 597-1205) and at 35 weeks gestational age (median 644 U/L, range 550-888).
Plasma ALP activity fluctuates considerably during the postnatal period in preterm infants. The plasma ALP activity is predominantly of bony origin although an intestinal ALP isoenzyme may be present in the early postnatal period; it is usually undetectable by 5-6 weeks of age." Postnatal events, including inadequate dietary mineral intake, impaired or altered vitamin D metabolism and morbidity are all likely to affect plasma ALP activity. Our data suggest that ALP enzyme release may be pulsatile and dependent on both gestational age at birth and postnatal age. Both age variables need to be considered when interpreting plasma ALP activity in the preterm infant.
